Patents by Inventor Mads Aaboe Jensen

Mads Aaboe Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20240085402
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 20, 2023
    Publication date: March 14, 2024
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 11852627
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 26, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20230296587
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 21, 2023
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • OLIGONUCLEOTIDES FOR MODULATING CD73 EXON 7 SPLICING
    Publication number: 20230122753
    Abstract: The present invention relates to antisense oligonucleotides that are complementary to mammalian CD73 (NT5E) pre-mRNA, wherein the antisense oligonucleotides are capable of modulating the splicing of mammalian CD73 pre-mRNA exon 7. Splice modulation of mammalian CD73 exon 7 is beneficial for a range of medical disorders, including disorders in the field of immune-oncology.
    Type: Application
    Filed: August 26, 2022
    Publication date: April 20, 2023
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Gianluigi LICHINCHI, Jonas VIKESAA
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20220146496
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 11320421
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20200348286
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 10739332
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 11, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 10718753
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: July 21, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20200057052
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 10494633
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 3, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20190310244
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 10, 2019
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • THERAPEUTIC OLIGONUCLEOTIDES CAPTURE AND DETECTION
    Publication number: 20190284621
    Abstract: The present invention relates to the detection of therapeutic modified oligonucleotides in biological samples and an adaptor oligonucleotide (capture probe) which enables a quantitative PCR based detection method and the sequencing of modified oligonucleotides. The invention provides novel adaptor probes for use in detecting therapeutic oligonucleotides and for in vivo discovery of preferred therapeutic oligonucleotide sequences.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Morten LINDOW, Jonas VIKESAA
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20170191064
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE
    Publication number: 20160108396
    Abstract: The disclosure relates to oligomers capable of targeting RNA expressed from the human C9ORF72 gene containing a pathogenic hexanucleotide repeat expansion. Such oligomers are useful for, among other things, reducing or eliminating C9ORF72 RNA and/or proteins translated therefrom, and treating or preventing diseases or disorders caused by, or associated with, hexanucleotide repeat expansion, including familial frontotemporal dementia (FTD) and familial amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: August 14, 2015
    Publication date: April 21, 2016
    Inventors: Mads Aaboe Jensen, Morten Lindow